Results 31 to 40 of about 2,131 (185)

Effects of Fremanezumab on Medication Overuse in Japanese Chronic Migraine Patients: Post Hoc Analysis of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

Neurology and Therapy, 2023
Introduction Chronic migraine (CM) patients commonly take acute headache medications, often resulting in medication overuse (MO). This post hoc analysis evaluated the efficacy of fremanezumab in CM patients from Japan with and without MO, which is not ...
Noboru Imai, Yuki Isogai, Yoshiyuki Shibasaki, Masami Nakai, Miki Ishida, Xiaoping Ning, Nobuyuki Koga   +6 more
doaj   +1 more source

Early onset of efficacy with fremanezumab in patients with episodic and chronic migraine: subanalysis of two phase 2b/3 trials in Japanese and Korean patients

The Journal of Headache and Pain, 2022
Background Early onset of action has become recognized as an important efficacy feature of preventive migraine treatment, which can help overcome adherence issues commonly associated with older medications.
Takao Takeshima, Masami Nakai, Yoshiyuki Shibasaki, Miki Ishida, Byung-Kun Kim, Xiaoping Ning, Nobuyuki Koga   +6 more
doaj   +1 more source

Real-world effectiveness of fremanezumab in migraine patients initiating treatment in the United States: results from a retrospective chart study

The Journal of Headache and Pain, 2022
Background The efficacy and tolerability of fremanezumab, a fully humanized monoclonal antibody (IgG2Δa) that selectively targets calcitonin gene-related peptide (CGRP) and is approved for the preventive treatment of migraine in adults, have been ...
Maurice T. Driessen, Joshua M. Cohen, Oscar Patterson-Lomba, Stephen F. Thompson, Michael Seminerio, Karen Carr, Todor I. Totev, Rochelle Sun, Erica Yim, Fan Mu, Rajeev Ayyagari   +10 more
doaj   +1 more source

Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)

The Journal of Headache and Pain, 2022
Background Fremanezumab has demonstrated to be effective, safe, and tolerated in the prevention of episodic or chronic migraine (CM) in randomized, placebo-controlled trials (RCTs).
Piero Barbanti, Gabriella Egeo, Cinzia Aurilia, Florindo d’Onofrio, Maria Albanese, Ilaria Cetta, Paola Di Fiore, Maurizio Zucco, Massimo FilippiBonassi, Francesco Bono, Claudia Altamura, Stefania Proietti, Stefano Bonassi, Fabrizio Vernieri, for the FRIEND-Study Group   +14 more
doaj   +1 more source

Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway: a subgroup analysis of the Finesse Study

The Journal of Headache and Pain, 2023
Background Monoclonal antibodies targeting the CGRP pathway are effective and safe for prophylactic treatment of episodic (EM) and chronic migraine (CM).
Andreas Straube, Gregor Broessner, Charly Gaul, Xenia Hamann, Joachim Hipp, Torsten Kraya, Lars Neeb   +6 more
doaj   +1 more source

CGRP-Targeted Therapy in Vestibular Migraine-How Strong Is the Evidence? [PDF]

Eur J Neurol
ABSTRACT Background Medications for migraine prevention targeting the calcitonin gene‐related peptide (CGRP) pathway have substantially reduced symptom burden in many patients that have failed previous treatment strategies. In contrast, data on treatment response to monoclonal antibodies (mAbs) or small molecule receptor antagonists (gepants) in ...
Tarnutzer AA, Castro Abarca P, Kaski D.
europepmc   +2 more sources

Real-world efficacy and tolerability of fremanezumab in adults with chronic migraine: a 3-month, single-center, prospective, observational study

, 2023
Background: Following the promising pre-marketing placebo-controlled randomized clinical trials of fremanezumab, post-marketing studies are necessary to verify efficacy and tolerability in various real-world settings.
Cullum, Christopher Kjaer, Christopher Kjaer Cullum, Chaudhry, Basit Ali, Faisal Mohammad Amin, Basit Ali Chaudhry, Do, Thien Phu, Amin, Faisal Mohammad, Thien Phu Do   +7 more
core   +1 more source

Scaling Approaches for Pediatric Dose Selection: The Fremanezumab (AJOVY^®) Journey to Select a Phase 3 Dose Using Pharmacokinetic Data from a Phase 1 Study

Pharmaceutics, 2021
Fremanezumab, a fully humanized IgG2Δa/kappa monoclonal antibody, selectively targets the calcitonin-gene-related peptide (CGRP) and prevents it from binding to the CGRP receptor.
Aksana Jones, Orit Cohen-Barak, Andrijana Radivojevic, Jill Fiedler-Kelly   +3 more
doaj   +1 more source

Fremanezumab: First Global Approval [PDF]

Drugs, 2018
Fremanezumab-vfrm (hereafter referred to as fremanezumab) [AJOVY™] is a fully humanized monoclonal antibody (IgG2Δa) developed by Teva Pharmaceuticals to selectively target calcitonin gene-related peptide (a vasodilatory neuropeptide involved in the pathophysiology of migraine).
openaire   +2 more sources

Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine

The Journal of Headache and Pain, 2022
Background Fremanezumab, a fully humanized monoclonal antibody (mAb; IgG2Δa) that selectively targets calcitonin gene-related peptide (CGRP), is approved for the preventive treatment of migraine in adults.
Maurice T. Driessen, Joshua M. Cohen, Stephen F. Thompson, Oscar Patterson-Lomba, Michael J. Seminerio, Karen Carr, Todor I. Totev, Rochelle Sun, Erica Yim, Fan Mu, Rajeev Ayyagari   +10 more
doaj   +1 more source